Promising research conducted by Dr. Ernest Wright and Dr. Jorge Barrio, both of UCLA's Jonsson Comprehensive Cancer Center, show two types of sodium-dependent glucose transports known as SGLT1 and SGLT2 are actively involved in glucose uptake into tumors. And that makes them prime targets for drug investigators.
New work from researchers at UCLA is shedding light on the delivery of glucose to tumor cells, particularly in pancreatic and prostate cancers. The research could offer new diagnostic procedures for detecting these cancers and, down the road, the use of inhibitors to cut down the amount of glucose delivered to the tumors, slowing down their growth.
Investigators at University College London have identified a compound that targets unusual knots frequently found inside faulty genes and determined that it proved effective in shrinking pancreatic tumors in mice. And while they say this particular compound isn't suitable for clinical testing, the team believes that another member of this family of medications could prove fruitful in fighting one of the most lethal cancers in the book.
NuCana is set to start a Phase III trial of Acelarin in patients with pancreatic cancerthis month, kicking off a surge into late-stage studies that will see it work on ovarian and biliary programs later this year. The Sofinnova Ventures-backed biotech is initiating the multi-front advance on the strength of Phase I/II data, details of which were presented at ASCO.
Roche's Ventana struck a deal with Halozyme Therapeutics to develop a companion diagnostic test to use with Halozyme's new pancreatic cancer drug, adding to a recent string of collaborations as the company continues to expand its industry footprint.
Aduro Biotech is picking up in 2015 where it left off last year, riding momentum into an upsized $119 million IPO to fund its breakthrough pancreatic cancer immunotherapy combo CRS-207 and GVAX.
In another step forward for cancer vaccine combos, Aduro Biotech announced Thursday that an investigator-led Phase II trial of its GVAX and CRS-207 for pancreatic cancer with Opdivo, Bristol-Myers Squibb's PD-1 drug, would begin.
Researchers at the University of North Carolina, Chapel Hill, have used electrical fields to deliver chemotherapy drugs to difficult tumors, and the small electrical charges have shown in animal tests to drive the therapies deep into solid tumors that were once hard to reach.
Pancreatic cancer has long loomed as one of the most aggressive killers, typically leaving patients with a poor prognosis and specialists with few options for effective treatment. But now a team at the University of Michigan in Ann Arbor says they have new reason to believe that a particular gene is responsible for the fast-spreading cancer--offering a clear target for drug developers.
Gilead Sciences' simtuzumab failed to meet its main goal in a Phase II pancreatic cancer trial, denting the potential of a therapy the company hopes can treat a wide range of malignancies.